SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Accounts Payable

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) (BCYPU) currently reports a accounts payable of $3.9M as of June 2026. That compares with $2.6M in the prior-year period — up 47.0% year over year. Use the charts on this page to explore SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s accounts payable history and peer comparisons.

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s accounts payable increased from $2.6M to $3.9M — a 47.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) reported $3.9M in accounts payable as of June 2026. That compares with $2.6M in the prior-year period — up 47.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $3.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt), and consider following BCYPU for alerts when major investors trade the stock.